NEKTAR THERAPEUTICS
Nektar Therapeutics (NASDAQ: NKTR) is a clinical-stage, research-based biopharmaceutical company focused on discovering and developing innovative immunomodulatory medicines. The company applies deep understanding of immunology to identify and create drug candidates that selectively induce, amplify, attenuate, or… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NEKTAR THERAPEUTICS does
In the company’s own words
Nektar Therapeutics (NASDAQ: NKTR) is a clinical-stage, research-based biopharmaceutical company focused on discovering and developing innovative immunomodulatory medicines. The company applies deep understanding of immunology to identify and create drug candidates that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes across autoimmune diseases and oncology indications.
Nektar's primary pipeline centers on rezpegaldesleukin, a potential first-in-class resolution therapeutic designed to stimulate regulatory T cells by targeting the interleukin-2 receptor complex. The company regained full rights to rezpegaldesleukin in April 2023 following termination of its license agreement with Eli Lilly and Company. The drug candidate is currently in Phase 2b clinical development for atopic dermatitis and alopecia areata, with Fast Track designations granted by the FDA for both indications. The company is also evaluating rezpegaldesleukin in type 1 diabetes through a clinical trial agreement with TrialNet.
In oncology, Nektar develops NKTR-255, an investigational biologic targeting the interleukin-15 pathway to activate innate and adaptive immunity for cancer treatment. The company is conducting select developmental studies in combination with cell therapies and checkpoint inhibitors while exploring strategic partnership opportunities. Additional pipeline programs include NKTR-0165 and NKTR-0166, preclinical TNF receptor type II agonist assets being developed for autoimmune diseases, and NKTR-422, a PEG-modified colony stimulating factor program targeting inflammation and fibrosis.
Nektar's technology platform centers on advanced polymer conjugate technology involving polyethylene glycol conjugation, commonly known as PEGylation. This proven technology has supported the development of multiple approved products including Neulasta, CIMZIA, and MIRCERA. In December 2024, Nektar sold its manufacturing facility in Huntsville, Alabama to Gannet BioChem and retained an approximate twenty percent equity investment, while maintaining supply agreements for polyethylene glycol reagents essential to its drug development programs.
The company operates as a smaller reporting company and is not a well-known seasoned issuer. Nektar maintains collaboration partnerships with various biotechnology and pharmaceutical companies and continues investing substantially in research and development to advance its pipeline of immunomodulatory drug candidates.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 906709
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NEKTAR THERAPEUTICS — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NEKTAR THERAPEUTICS’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NEKTAR THERAPEUTICS and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NEKTAR THERAPEUTICS's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NEKTAR THERAPEUTICS's last four quarterly filings that the numbers alone won't show?”